share_log

Evercore ISI Group Maintains Outperform on Editas Medicine, Lowers Price Target to $5

Benzinga ·  Dec 16 21:29  · Ratings

Evercore ISI Group analyst Liisa Bayko maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and lowers the price target from $7 to $5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment